Lyra Therapeutics Inc reports results for the quarter ended in June - Earnings Summary

Lyra Therapeutics

09/08/2022 14:30

* Lyra Therapeutics Inc  LYRA.OQ  reported a quarterly
adjusted
loss of 43 cents​​ per share for the quarter ended in June. The
mean expectation of four analysts for the quarter was for a loss
of 37 cents per share.
    * Revenue was $407.00 thousand​; analysts expected $1.44
million. 
    * Lyra Therapeutics Inc's reported EPS for the quarter was a
loss
of 43 cents​.
    * The mean earnings estimate of analysts had risen by
about 34.1%
in the last three months.​ 
    * In the last 30 days there have been no negative revisions
of
earnings estimates 
    * Lyra Therapeutics Inc shares had risen by 16.1% this
quarter and
gained 50.5% so far this year.
    * The company reported a quarterly loss of $14.48 million.
    * Wall Street's median 12-month price target for Lyra
Therapeutics
Inc is $16.50 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 4 "strong buy" or
"buy," 1 "hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data August 9
at 01:30 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2022      -0.37          -0.43          Missed
 Mar. 31 2022      -0.91          -0.54          Beat
 Dec. 31 2021      -0.79          -1.05          Missed
 Sep. 30 2021      -0.73          -0.85          Missed